VALIDGFR; method VALIDation and evaluation of non-radioactive methods to measure Glomerular Filtration Rate

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509156-34-02

Enrollment

200

Registered

2024-06-05

Start date

2025-02-24

Completion date

Unknown

Last updated

2025-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease Kidney Failure

Brief summary

mGFR determined using 125I-Iothalamate and 131I-hippuran, mGFR determined using iohexol

Interventions

DRUGAMINOHIPPURIC ACID

DRUGIOTALAMATE MEGLUMINE

DRUGAdrenaline CF 1 mg/ml

DRUGoplossing voor injectie

DRUGOMNIPAQUE 300 mg I/ml

DRUGTavegyl 1 mg/ml

DRUGSODIUM IOTALAMATE (125I)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
mGFR determined using 125I-Iothalamate and 131I-hippuran, mGFR determined using iohexol	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026